Clinical Trials Directory

Trials / Unknown

UnknownNCT00773539

A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
78 (estimated)
Sponsor
Herz-Zentrums Bad Krozingen · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Transvenous pulmonary vein (PV) isolation using radiofrequency energy is an effective treatment for atrial fibrillation (1-4). However, rare but potentially life threatening complications such as thromboembolism (5), PV stenosis (5-10), left atrium-oesophageal fistula (11) and inflammatory syndromes (12) have been described. In preliminary studies an alternate approach using cryoenergy induces less endothelial disruption/ thrombus formation (13), preserves the extra cellular matrix and creates lesions with well-delineated border zones (14). Therefore, cryoenergy seems to be the ideal form of energy to safely perform PV isolation. We therefore hypothesise that in the setting of PV isolation for the treatment of atrial fibrillation (AF) cryoenergy is less traumatic and therefore reduces systemic inflammatory responses compared to radiofrequency energy. 78 patients presenting with symptomatic intermittent or persistent AF will be randomised to PV isolation with either radiofrequency (26 patients open irrigated tip, 26 patients closed irrigated tip) or cryoenergy (26 patients with cryoballoon). Systemic markers of cell damage and inflammatory response (t-troponin, CK, CK-MB, vWF, PAI-1, micro particles, platelet activation/overall function, CRP, IL-6, IL-8, IL-10, TNF alpha, procalcitonin) will be monitored before, during and 48h after the procedure. Further endpoints include time to PV-isolation and procedure related complications. Six month clinical follow-up will focus on freedom from AF and cardiovascular events.

Conditions

Interventions

TypeNameDescription
PROCEDUREPVI using an open irrigated tip cathetertransseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
PROCEDUREPVI using a closed irrigated tip cathetertransseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
PROCEDUREPVI using a cryoballoontransseptal PVI using the cryoballoon from CRYOCATH

Timeline

Start date
2008-07-01
Primary completion
2009-02-01
Completion
2009-08-01
First posted
2008-10-16
Last updated
2008-10-16

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00773539. Inclusion in this directory is not an endorsement.